Industry Satellite Symposia

The American Society for Radiation Oncology (ASTRO) has reviewed and approved these symposia as appropriate for presentation as an Industry Satellite Symposium. The symposia constitute the content and views of the provider and is not part of the official ASTRO Annual Meeting program.


Sunday, October 23, 2022

6:00 p.m. - 8:00 p.m. | Brainlab Novalis Circle Symposium - Clinical Applications of Elements and ExacTrac Dynamic

Location: Grand Hyatt San Antonio, Lone Star Salon A/B
600 E. Market Street
San Antonio, TX 78205

Dinner will be provided starting at 6:00 p.m.

For more information or to register for our live symposium in San Antonio, please visit www.novaliscircle.org.

Not going to San Antonio? Tune in to our live web broadcast instead! For more information or to register for our live web broadcast, please visit www.novaliscircle.org.

CME Credits: This is a Non-CME program.

Target Audience: This meeting is intended for radiation oncologists and medical physicists.

Learning Objectives:

  1. Review ExacTrac Dynamic utilization for CNS patients.
  2. Understand the value of real-time IGRT for DIBH treatments.
  3. Discuss the role of prostatic drift monitoring for margin reduction in prostate SBRT.
  4. Evaluate benefits of longitudinal management of patients with intracranial metastasis.


Topics: Presentations will cover general radiosurgery applications of ExacTrac Dynamic, including first results for novel DIBH setup and monitoring for breast patients and real-time organ motion management for prostate cancer patients. Clinical discussions will also cover a general review of physician-oriented tools for management of patients with intracranial metastasis; from diagnosis to treatment and re-treatment.

Faculty:

  1. Amol Ghia, MD, MD Anderson Cancer Center, Houston, Texas, United States
    Presentation Topic: A Refreshed Focus for IGRT Setup and Monitoring in CNS Applications
  1. Wenyin Shi, MD, PhD, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
    Presentation Topic: Improved Longitudinal Care for Patients with Intracranial Metastases via the Use of Indication-Specific Tools
  2. Thierry Gevaert, PhD, Universitair Ziekenhuis Brussel, Belgium
    Presentation Topic: Margin Reduction Opportunity with Novel DIBH Workflow Within ExacTrac Dynamic
  3. Thomas Kole, MD, PhD, Valley-Mount Sinai Comprehensive Cancer Care, Paramus, New Jersey, United States
    Presentation Topic: Improved SBRT Capabilities with 6-D Setup and Prostatic Drift Monitoring


This activity is independently supported by Brainlab.


Sunday, October 23, 2022

6:00 p.m. – 8:00 p.m. | Harnessing Novel Synergies to Improve Survival in Aggressive Tumors: Clinical Insights on Tumor Treating Fields Within Multimodal Care

Location: Grand Hyatt San Antonio River Walk, Texas Ballroom Salon A/B
600 E. Market Street
San Antonio, TX 78205

6:00 p.m. – 6:30 p.m.: Registration and Dinner
6:30 p.m. – 8:00 p.m.: Symposium

For more information or to register for our live symposium in San Antonio, please visit peerview.com/SanAntonio22-Live.

Not going to San Antonio? Register for the live virtual symposium instead! For more information or to register, please visit peerview.com/SanAntonio22-Live.

Accreditation:
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

CME Credits: PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience: This activity has been designed to meet the educational needs of radiation oncologists, medical oncologists, neuro-oncologists and other health care professionals involved in the care of patients with solid tumors.

Learning Objectives:
Upon completion of this activity, participants should be better able to:

  • Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM).
  • Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal and gynecologic cancers.
  • Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM and other solid tumors.
  • Employ evidence and team-based strategies to mitigate and manage AEs associated with novel LRTs (eg,TTFields) in patients with solid tumors.


This activity is supported through an educational grant from Novocure Inc.


Monday, October 24, 2022

5:30 p.m. - 7:00 p.m. | Innovations in the Treatment of LA SCCHN
Enhancing Antitumor Activity through IAP Antagonism

Location: Grand Hyatt San Antonio, Lone Star Salon A/B
600 E. Market Street
San Antonio, TX 78205

5:30 p.m. – 6:00 p.m.: Registration and Dinner
6:00 p.m. – 7:00 p.m.: Symposium

For more information or to register for our live symposium in San Antonio, please visit www.reachmd.com/scchn.

Not going to San Antonio? Tune in to our live web broadcast instead! For more information or to register for our live web broadcast, please visit www.reachmd.com/scchn-virtual.

Accreditation: In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Provider: AGILE - Academy for Global Interprofessional Learning and Education - designs, develops and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps health care professionals improve competence, performance and patient outcomes.

CME Credits: Global Learning Collaborative designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Target audience:
Medical oncologists, pathologists, radiation oncologists and other health care professionals treating patients with head and neck cancers.
 
Learning Objectives:
  1. Describe factors that contribute to patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) experiencing disease progression/recurrence.
  2. Assess the risks, benefits and limitations of agents currently available as treatment options for the management of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
  3. Differentiate the mechanisms of action of agents currently being investigated for the treatment of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) from those of currently available treatment options.
  4. Assess the therapeutic potential of agents being investigated for the management of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

Agenda Topics:
*Subject to change.
 
Topic Speaker(s)
Welcome and Introduction Kevin Harrington, MD
Raising Awareness of Emergent Findings in the Treatment of LA SCCHN Barbara Burtness, MD
Why the Excitement Associated with IAP Antagonists in LA SCCHN Ari Rosenberg, MD
Focus on Inhibitor of Apoptosis Protein (IAP) Antagonists Mechanism of Action in the Tumor Microenvironment (shown in 3-D) Kevin Harrington, MD
Panel Discussion: IAP Antagonists in LA SCCHN: New Potential Options for Patients Kevin Harrington, MD (moderator)
Barbara Burtness, MD
Ari Rosenberg, MD
Q&A and Closing Remarks Kevin Harrington, MD (moderator)
Barbara Burtness, MD
Ari Rosenberg, MD
Faculty:
  1. Barbara Burtness, MD
  2. Kevin Harrington, MD
  3. Ari Rosenberg, MD
 
This activity is supported by an independent educational grant from Healthcare business of Merck KGaA, Darmstadt, Germany.

American Society for Radiation Oncology
251 18th Street South, 8th Floor
Arlington, VA 22202
Telephone: 703-502-1550
www.astro.org

TERMS OF USE & PRIVACY POLICY

Connect With Us: